356 related articles for article (PubMed ID: 34432543)
21. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D
Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786
[TBL] [Abstract][Full Text] [Related]
22. A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
Quillet JC; Siani-Rose M; McKee R; Goldstein B; Taylor M; Kurek I
Sci Rep; 2023 Aug; 13(1):13022. PubMed ID: 37608004
[TBL] [Abstract][Full Text] [Related]
23. Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits.
Montagner PSS; Medeiros W; da Silva LCR; Borges CN; Brasil-Neto J; de Deus Silva Barbosa V; Caixeta FV; Malcher-Lopes R
Front Psychiatry; 2023; 14():1210155. PubMed ID: 37671290
[TBL] [Abstract][Full Text] [Related]
24. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
25. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
[TBL] [Abstract][Full Text] [Related]
26. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study.
Hacohen M; Stolar OE; Berkovitch M; Elkana O; Kohn E; Hazan A; Heyman E; Sobol Y; Waissengreen D; Gal E; Dinstein I
Transl Psychiatry; 2022 Sep; 12(1):375. PubMed ID: 36085294
[TBL] [Abstract][Full Text] [Related]
27. Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.
Mazza JAS; Ferreira LS; Martins-Vieira AF; Beserra DDL; Rodrigues VA; Malcher-Lopes R; Caixeta FV
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931353
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents.
Lamy M; Pedapati EV; Dominick KL; Wink LK; Erickson CA
Paediatr Drugs; 2020 Oct; 22(5):473-483. PubMed ID: 32686015
[TBL] [Abstract][Full Text] [Related]
29. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.
Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD
Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
[TBL] [Abstract][Full Text] [Related]
31. An Introduction to the Psychopharmacology of Children and Adolescents With Autism Spectrum Disorder.
Earle JF
J Child Adolesc Psychiatr Nurs; 2016 May; 29(2):62-71. PubMed ID: 27279529
[TBL] [Abstract][Full Text] [Related]
32. Psychopharmacological interventions in autism spectrum disorder.
Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
Lamy M; Erickson CA
Curr Probl Pediatr Adolesc Health Care; 2018 Oct; 48(10):250-264. PubMed ID: 30262163
[TBL] [Abstract][Full Text] [Related]
34. Lurasidone for the treatment of irritability and anger in autism spectrum disorders.
McClellan L; Dominick KC; Pedapati EV; Wink LK; Erickson CA
Expert Opin Investig Drugs; 2017 Aug; 26(8):985-989. PubMed ID: 28685626
[TBL] [Abstract][Full Text] [Related]
35. The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review.
Rossignol DA; Frye RE
Front Pediatr; 2014; 2():87. PubMed ID: 25202686
[TBL] [Abstract][Full Text] [Related]
36. Autism and associated disorders: cannabis as a potential therapy.
Babayeva M; Assefa H; Basu P; Loewy Z
Front Biosci (Elite Ed); 2022 Jan; 14(1):1. PubMed ID: 35320905
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study.
Ma L; Platnick S; Platnick H
Cureus; 2022 Aug; 14(8):e28442. PubMed ID: 36176817
[TBL] [Abstract][Full Text] [Related]
38. Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Salazar de Pablo G; Pastor Jordá C; Vaquerizo-Serrano J; Moreno C; Cabras A; Arango C; Hernández P; Veenstra-VanderWeele J; Simonoff E; Fusar-Poli P; Santosh P; Cortese S; Parellada M
J Am Acad Child Adolesc Psychiatry; 2023 Feb; 62(2):151-168. PubMed ID: 35470032
[TBL] [Abstract][Full Text] [Related]
39. A primer on medicinal cannabis safety and potential adverse effects.
Arnold JC
Aust J Gen Pract; 2021 Jun; 50(6):345-350. PubMed ID: 34059837
[TBL] [Abstract][Full Text] [Related]
40. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
